Podcasts about Keynote

In this special keynote episode, we're sharing The Life-Saving Magic of Herbing It Up with herbalist, educator, and community leader Lottie Spady, recorded live at the 2025 Great Lakes Herb Faire. In this powerful and heartfelt talk, Lottie shares how her journey into herbalism transformed not only her physical health, but also her sense of purpose, community, and connection to the natural world. Through her story, we're reminded of the deep, life-changing potential of building relationships with plants as true allies. Huge thanks to Lottie for granting permission to share this keynote, and to Anna and the entire Great Lakes Herb Faire team for so generously providing the recording. If this talk resonates with you, be sure to check out everything the Great Lakes Herb Faire has to offer… Learn more about the Faire | GreatLakesHerbFaire.com The Faire offers recordings from past events (including this keynote), with dozens of classes available from over the years. Most are available individually, or as part of larger bundles. You can BROWSE THE RECORDINGS HERE.  And be sure to check out Lottie's work with Earthseed Detroit, where she focuses on community herbalism, education, and accessible wellness: Earthseed Detroit | EarthseedDetroit.com Thanks for listening, and we hope you enjoy this inspiring keynote from Lottie Spady. ⚠️ DISCLAIMER This content is for educational and entertainment purposes only. It is not intended to diagnose, treat, or cure any disease. Always consult with a qualified healthcare provider before making changes to your health regimen.

Today, on Notable Leaders' Radio, I speak with Stephanie Baker, Chief Experience Officer and artist. She highlights her journey of moving beyond achievement, sharing how embracing vulnerability, creativity, and leading with empathy has redefined what true success means, for herself, her teams, and those she mentors. In today's episode, we discuss: Reimagine your definition of success. Step back from titles and checkboxes. Ask yourself whether your work aligns with your core values and your true impact. When your work is a reflection of who you are, fulfillment finds you, not the other way around. Lead with empathy and inclusion. Performance isn't just about KPIs; it's about how people feel in your presence. When you foster empathy, inclusion, and psychological safety, you build teams that are resilient, innovative, and engaged at every level. Make becoming a lifelong pursuit. You don't have to have it all figured out. The most effective, impactful leaders are those who stay open to growth and keep redefining who they are—at work and in life. Protect your energy unapologetically. Learn to say "no"—and realize that it's a complete sentence. Being deliberate with your time and focus allows you to say "yes" to what truly matters and show up at your best. Give yourself permission to explore new interests. Try picking up something new—painting, mentoring, creating. You never know which hidden strengths or sources of joy are waiting for you. (Check out her paintings in the show notes. She is GIFTED!)   RESOURCES: Guest Bio: Stephanie Baker is a Senior operations executive with 20+ years of experience driving enterprise performance and operational excellence. A trusted partner to CEOs and Boards, I specialize in aligning people, processes, and technology to deliver exceptional outcomes for customers and employees. Recognized for building inclusive, engaged teams and leading transformational change with clarity and purpose. Website/Social Links www.linkedin.com/in/stephanie-baker-5833b78 slbaker28@gmail.com Belinda's Bio: Belinda is a sought-after Leadership Advisor, Coach, Consultant and Keynote speaker and a leading authority in guiding global executives, professionals and small business owners to become today's highly respected leaders. As the Founder of BelindaPruyne.com, Belinda works with such organizations as IBM, Booz Allen Hamilton, BBDO, The BAM Connection, Hilton, Leidos, Yale School of Medicine, Landis, and the Discovery Channel. Most recently, she redesigned two global internal advertising agencies for Cella, a leader in creative staffing and consulting. She is a founding C-suite and executive management coach for Chief, the fastest-growing executive women's network. Since 2020, Belinda has delivered more than 72 interviews with top-level executives and business leaders who share their inner journey to success; letting you know the truth of what it took to achieve their success in her Notable Leaders Radio podcast. She gained a wealth of expertise in the client services industry as Executive Vice President, Global Director of Creative Management at Grey Advertising, managing 500 people around the globe. With over 20+ years of leadership development experience, she brings industry-wide recognition to the executives and companies she works with. Whether a startup, turnaround, acquisition, or global corporation, executives and companies continue to turn to Pruyne for strategic and impactful solutions in a rapidly shifting economy and marketplace. Website: Belindapruyne.com Email Address: hello@belindapruyne.com LinkedIn: https://www.linkedin.com/in/belindapruyne  Facebook: https://www.facebook.com/NotableLeadersNetwork.BelindaPruyne/  Twitter: https://twitter.com/belindapruyne?lang=en  Instagram: https://www.instagram.com/belindapruyne/ 

**Content Warning** This episode includes discussions of sexual assault, which may be distressing for some listeners. Please listen with care.On this episode of the Hayek Program Podcast, David Schmidtz delivers a keynote lecture at the 2024 Markets & Society conference on the idea of self-governance. Drawing on examples from economics, moral philosophy, and higher education, Schmidtz argues that rational choice is less about optimization and more about choosing the frameworks within which decisions become meaningful. He examines the parallels between individual and corporate self-governance, the role of mission statements as “compasses” rather than formulas, and the dangers of over-specialization in academia. Along the way, he reflects on truth-seeking, academic freedom, moral education, and the human need for purposiveness, ultimately challenging universities to cultivate enduring capacities rather than narrow skill sets.Dr. David Schmidtz is Professor and Presidential Chair of Moral Science at West Virginia University's Chambers College of Business & Economics, Distinguished Affiliated Fellow with the F.A. Hayek Program for Advanced Study in Philosophy, Politics, and Economics at the Mercatus Center at George Mason University, and Editor-in-Chief of Social Philosophy & Policy. He has published numerous books, including Living Together: Inventing Moral Science (Oxford University Press, 2023), A Brief History of Liberty (Wiley Blackwell, 2011) coauthored with Jason Brennan, and his leading textbook Environmental Ethics What Really Matters, What Really Works (Oxford University Press, 2024) co-edited with Dan Shahar is now in its fourth edition.**This episode was recorded October 13, 2024.If you like the show, please subscribe, leave a 5-star review, and tell others about the show! We're available on Apple Podcasts, Spotify, Amazon Music, and wherever you get your podcasts.Check out our other podcast from the Hayek Program! Virtual Sentiments is a podcast in which political theorist Kristen Collins interviews scholars and practitioners grappling with pressing problems in political economy with an eye to the past. Subscribe today!Follow the Hayek Program on Twitter: @HayekProgramFollow the Mercatus Center on Twitter: @mercatusCC Music: Twisterium

AI is no longer theoretical. It is already changing how real estate decisions get made in underwriting, leasing, operations, marketing, asset management, and communication. In this special episode, I sit down with Steve Brown, AI futurist, bestselling author, and former senior leader at Google DeepMind and Intel. Steve is the Opening Keynote Speaker at the 2026 Midwest Real Estate Investor Conference (MREIC), and his message is clear: this shift is happening faster than most people realize—and "wait and see" is not a strategy. Steve's lens is built for real-world operating environments with real assets, teams, capital, and risk. He breaks down what AI changes at the workflow level, where it creates real leverage, and what actually matters now versus what can wait, so you do not waste time, money, or focus chasing the wrong thing. Steve explains what's accelerating in AI right now, what's likely to change over the next few years, and how real estate entrepreneurs and business owners should think about AI as a capability shift, not a collection of tools. In This Episode, Steve Breaks Down: Why AI is moving faster than even experts expected Why buying AI licenses is not a strategy (and what is) How smaller teams can operate like they're 5x or 10x their size The shift from "people are the engine" to "AI becomes the engine" What it takes to rethink workflows, not just adopt tools The biggest fears, misconceptions, and early implementation mistakes leaders make We also dig into the real competitive risk ahead: you won't lose to AI, you'll lose to someone who uses AI better than you. That applies directly to real estate investors. If you own rental properties, manage assets, raise capital, or run a real estate business, this conversation will sharpen how you think about leverage, workflows, and long-term competitiveness. MREIC 2026: Opening Keynote Details Midwest Real Estate Investor Conference (MREIC) DeVos Place Conference Center | Grand Rapids, Michigan April 27–28, 2026 Steve Brown Opening Keynote: Monday, April 27 at 9:00 AM Keynote Title: Navigating What's Next: Practical AI Strategy for Real Estate Investors and Operators Steve will also host a VIP Luncheon at 12:30 PM for attendees who want to go deeper on practical AI strategy and real-world implementation. Learn more and get tickets: midwestreiconference.com About Steve Brown Steve Brown is an AI futurist and former executive at Google DeepMind and Intel. He spent decades helping Fortune 100 companies navigate digital transformation and now advises organizations on how to thrive in the AI era. He is the author of The AI Ultimatum, written specifically for business leaders who want to understand and implement AI strategically. Learn more at: stevebrown.ai Today's episode is brought to you by Green Property Management, managing everything from single family homes to apartment complexes in the West Michigan area. www.livegreenlocal.com And RCB & Associates, helping Michigan-based real estate investors and small business owners navigate the complex world of health insurance and Medicare benefits. www.rcbassociatesllc.com

Time Stamps:00:00:00 Community Guest Intros00:05:00 FULL Breakdown On The Next Generation Xbox At The GDC 2026 Keynote With Jason Ronald! ALL Of The BIG News!01:04:00 Who Is The Next Generation Really For?01:37:00 Panel Outros and Special Message

Paulina McPadden thinks the best way to frame international trading is to look at the market share of U.S. companies versus the rest of the world, pointing to a smaller percentage of total companies making up a larger percentage of global valuations. She adds her thoughts on international financial stocks as a potential opportunity. Later, Paulina notes that she'll be attending Nvidia's (NVDA) GTC 2026 Keynote and explains the company's significance to the global AI trade. She highlights TSMC (TSM) and ASML (ASML) as international names that provide the "backbone" to global semiconductor manufacturing. Paulina then shares thoughts on other international equities such as Spotify (SPOT).======== Schwab Network ========Empowering every investor and trader, every market day.Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – / schwabnetwork Follow us on Facebook – / schwabnetwork Follow us on LinkedIn - / schwab-network About Schwab Network - https://schwabnetwork.com/about======== Schwab Network ========Empowering every investor and trader, every market day.Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – / schwabnetwork Follow us on Facebook – / schwabnetwork Follow us on LinkedIn - / schwab-network About Schwab Network - https://schwabnetwork.com/about

Esteban Kolksy, Chief Distiller at Constellation Research, closed out the CRM Playas IRL (In Real Life) event in Atlanta with a provocative keynote the debunked enterprise AI myths, while making a case for where the value in AI truly lies. After Kolsky left the stage, we broke down his main points on why LLMs are becoming commodities, and why proper enterprise AI is superior to out-of-the-box frontier models. Is AI "intelligent" - or a fascimle of intelligence - and why does this matter? We argued, at times, before landing on why Kolsky hates context graphs, and why I believe the misuse of the word "grounding" holds us back. This keynote was worth hashing out: there are big takeaways for customers that want to avoid lock-in, and to accomplish something better with AI by making AI a strategic part of infrastructure, rather than a not-very-smart chatbot.

In this episode of the Oncology Brothers podcast, we welcomed Dr. Petros Grivas, medical oncologist from the Fred Hutch Cancer Center, who walked through practice-changing and practice-reinforcing data across bladder cancer, kidney cancer, and prostate cancer. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: X/Twitter: https://twitter.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ Key topics discussed included: CREST & POTOMAC: IO-BCG combination data in high-risk BCG-naive NMIBC, both demonstrating a hazard ratio of 0.68 for DFS / EFS. EV-304/KEYNOTE-B15: established EV-Pembrolizumab as the new perioperative standard of care for resectable muscle-invasive bladder cancer regardless of cisplatin eligibility, with a pathological complete response rate of 56% and overall survival hazard ratio of 0.65. LITESPARK-022 & LITESPARK-011: data exploring Belzutifan combinations in adjuvant and refractory RCC settings, while managing key toxicities of anemia and hypoxia. CAPITELLO-281: evaluating capivasertib in PTEN-deficient metastatic hormone-sensitive prostate cancer, where patient related outcomes were reported.  Join us for this comprehensive discussion covering the latest GU oncology advances that will directly impact your clinical practice. Don't forget to like, subscribe, and check out our other episodes for more insights on oncology! #GUASCO2026, #BladderCancer, #RenalCellCarcinoma, #ProstateCancer, #OncBrothers

Today, we are joined by Felipe Gomez, a keynote pianist and business leader. His powerful keynotes provide an immersive and multi-sensory experience, inspiring organizations to unleash individual and collective virtuosity. Using his piano to highlight poignant topics, Felipe and Mike discuss the power of music, how to create tension and release in leadership, and how to incorporate musical principles into your personal and professional life.   Step beyond the ordinary at Caribe Royale Orlando, where Color Outside the Lines isn't just a tagline—it's a way of doing meetings differently. This AAA Four Diamond all-suite resort offers 1,337 contemporary suites and villas, 260,000 sq. ft. of versatile meeting space, and flexible outdoor venues like The Grove. Dining highlights include the luxurious Venetian Chop House and interactive Stadium Club®, blending elevated cuisine with unforgettable group experiences. Every detail is designed to inspire creativity, spark connection, and elevate your meetings to extraordinary.

Today, on Notable Leaders' Radio, I speak with Elizabeth Haggerty,  EVP Customer Solutions, America's Division, CRH. She highlights how navigating life's and career pivots, unexpected business challenges, and a life-changing health diagnosis led her to discover untapped reserves of courage and resilience, offering real-life strategies to thrive through uncertainty and continual growth. In today's episode, we discuss: Adopt the "one foot in, one foot out" approach. When considering a new role or industry, bring core skills you already have while stretching into new territory, so you're growing without completely untethering yourself. Let your setbacks refine, not define, you. When a business is sold, or a role ends abruptly, even through being fired, treat it as a painful but powerful pivot point, not a verdict on your worth or future potential. Integrate joy and self-care into your life. Make space for passions, hobbies, and relationships outside of work. These experiences not only enhance your overall well-being but also give you energy and perspective to face professional challenges with renewed spirit. Redefine your identity beyond job titles. Reflect on how external achievements and positions have shaped your sense of self. Shift your focus from titles to your skill sets, values, and unique contributions. This empowers you to navigate transitions and derive fulfillment from multiple aspects of life. Release the need to do everything alone. Accept that asking for help is a sign of wisdom, not weakness. Rely on your team's expertise and focus on asking insightful questions. This collaborative approach strengthens outcomes and develops your leadership. Guest Bio: Elizabeth Haggerty is a high-impact executive with over a 35-year history of driving growth and profitability in the building products industry.   Starting in the HVAC industry leading global product and channel P&Ls before transitioning to the industrial material products space where she has led large P&L businesses and key customer growth strategies.   Liz has experience in green fielding businesses as well as leading turn arounds and corporate carve-outs.   All of this done through building and developing high performing teams and investing in leadership development.  She has a bachelor's and master's degree in metallurgical engineering and an MBA.  Elizabeth has been recognized by:  Glass Magazine as one of the industry's Most Influential People,  Engineered Systems Magazine as 20 Women to Watch  HVAC and by Industry Week for women in manufacturing.   She was also recognized by the Manufacturing Institute a Women in Manufacturing Step Ahead Honoree in 2021. Website/Social Links LinkedIn: https://www.linkedin.com/in/elizabeth-haggerty-81885115/  Belinda's Bio: Belinda is a sought-after Leadership Advisor, Coach, Consultant and Keynote speaker and a leading authority in guiding global executives, professionals and small business owners to become today's highly respected leaders. As the Founder of BelindaPruyne.com, Belinda works with such organizations as IBM, Booz Allen Hamilton, BBDO, The BAM Connection, Hilton, Leidos, Yale School of Medicine, Landis, and the Discovery Channel. Most recently, she redesigned two global internal advertising agencies for Cella, a leader in creative staffing and consulting. She is a founding C-suite and executive management coach for Chief, the fastest-growing executive women's network. Since 2020, Belinda has delivered more than 72 interviews with top-level executives and business leaders who share their inner journey to success; letting you know the truth of what it took to achieve their success in her Notable Leaders Radio podcast. She gained a wealth of expertise in the client services industry as Executive Vice President, Global Director of Creative Management at Grey Advertising, managing 500 people around the globe. With over 20+ years of leadership development experience, she brings industry-wide recognition to the executives and companies she works with. Whether a startup, turnaround, acquisition, or global corporation, executives and companies continue to turn to Pruyne for strategic and impactful solutions in a rapidly shifting economy and marketplace. Website: Belindapruyne.com Email Address: hello@belindapruyne.com LinkedIn: https://www.linkedin.com/in/belindapruyne  Facebook: https://www.facebook.com/NotableLeadersNetwork.BelindaPruyne/  Twitter: https://twitter.com/belindapruyne?lang=en  Instagram: https://www.instagram.com/belindapruyne/ 

In this episode of the New Books Network, I sat down with the contributors of Psychoanalytic Explorations into the Primal Relationship in Japan and India (Routledge, 2025) to discuss the profound psychic textures of the East. Moving away from the traditional Eurocentric focus on the Oedipal complex, this volume investigates the "primal relationship"—the foundational bond between mother and infant—and how it is uniquely structured within the cultural contexts of Japan and India. The authors challenge the universality of Western clinical models, proposing instead that the maternal matrix in these societies offers a different roadmap for understanding the self, intimacy, and dependency. Osamu Kitayama is a Training and Supervising Analyst at the Japan Psychoanalytic Society, Professor Emeritus at Kyushu University, and President of Hakuoh University. He served as President of the Japan Psychoanalytic Society from 2016–2019 and con tinues to work with patients in private practice. He has authored numerous articles on culturally oriented psychoanalysis and books.Jhuma Basak is a Training and Supervising Analyst at the Indian Psychoanalytical Society. She has published on culture and gender. Over the past 20 years, she has pre sented at IPA Congresses along with the first Keynote from Asia-Pacific, 4th IPA-region at the 53rd IPA Congress (International Journal of Psychoanalysis). A past Co-chair of COWAP Asia-Pacific, she co-edited Psychoanalytic and Socio-Cultural Perspectives on Women in India: Violence, Safety and Survival (2021).Ashis Roy, PhD, is a psychoanalyst (IPS Kolkata/IPA London) and faculty member at the China-American Psychoanalytic Alliance (CAPA). With an extensive background in clinical training and institutional building at Ambedkar University Delhi, his work emphasizes the dialogue between clinical practice and Asian cultural dynamics. He is a host for the New Books Network and the author of the recently released book, Intimate Hindu-Muslim Relationships: A Psychoanalytic Exploration of the Self and the Other (2024). Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/psychoanalysis

En este episodio, Brian, Tom y Matt Galsky analizan los datos del estudio B15 sobre terapia neoadyuvante para el cáncer de vejiga músculo-invasivo cisplatino-elegible, centrándose en la eficacia de EV-Pembro en comparación con cisplatino-gemcitabina. Exploran la SLE, SG y las implicaciones de la duración del tratamiento así como su individualización. La conversación también aborda el papel del ctDNA en las decisiones terapéuticas, las histologías alternativas y la importancia de la terapia sistémica neoadyuvante. El episodio concluye con reflexiones sobre las futuras direcciones en el tratamiento del cáncer de vejiga y la relevancia de los estudios en curso.

In this episode of the New Books Network, I sat down with the contributors of Psychoanalytic Explorations into the Primal Relationship in Japan and India (Routledge, 2025) to discuss the profound psychic textures of the East. Moving away from the traditional Eurocentric focus on the Oedipal complex, this volume investigates the "primal relationship"—the foundational bond between mother and infant—and how it is uniquely structured within the cultural contexts of Japan and India. The authors challenge the universality of Western clinical models, proposing instead that the maternal matrix in these societies offers a different roadmap for understanding the self, intimacy, and dependency. Osamu Kitayama is a Training and Supervising Analyst at the Japan Psychoanalytic Society, Professor Emeritus at Kyushu University, and President of Hakuoh University. He served as President of the Japan Psychoanalytic Society from 2016–2019 and con tinues to work with patients in private practice. He has authored numerous articles on culturally oriented psychoanalysis and books.Jhuma Basak is a Training and Supervising Analyst at the Indian Psychoanalytical Society. She has published on culture and gender. Over the past 20 years, she has pre sented at IPA Congresses along with the first Keynote from Asia-Pacific, 4th IPA-region at the 53rd IPA Congress (International Journal of Psychoanalysis). A past Co-chair of COWAP Asia-Pacific, she co-edited Psychoanalytic and Socio-Cultural Perspectives on Women in India: Violence, Safety and Survival (2021).Ashis Roy, PhD, is a psychoanalyst (IPS Kolkata/IPA London) and faculty member at the China-American Psychoanalytic Alliance (CAPA). With an extensive background in clinical training and institutional building at Ambedkar University Delhi, his work emphasizes the dialogue between clinical practice and Asian cultural dynamics. He is a host for the New Books Network and the author of the recently released book, Intimate Hindu-Muslim Relationships: A Psychoanalytic Exploration of the Self and the Other (2024). Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/new-books-network

Have you streamed this episode yet?In this special keynote spotlight episode of Problem Solved, IISE's Frank Reddy sits down with Dr. Mark Benden, researcher, inventor of nearly 30 patents, and longtime leader in ergonomics innovation. With more than four decades of experience across military service, industry, and academia, Dr. Benden has helped generate over $2.5 billion in economic impact through human-centered design and workplace innovation.In this conversation, he shares:Join us for this inside look at one of AEC's keynote voices. And don't miss Problem Solved LIVE on-site at AEC, where we'll be capturing insights from innovators shaping the future of ergonomics.Applied Ergonomics Conference sponsored by Applied Ergonomics SocietyLearn more about The Institute of Industrial and Systems Engineers (IISE)Problem Solved on LinkedInProblem Solved on YouTubeProblem Solved on InstagramProblem Solved on TikTokProblem Solved Executive Producer: Elizabeth GrimesInterested in contributing to the podcast or sponsoring an episode? Email egrimes@iise.org

We had the opportunity to dive into the evolving landscape of bladder cancer treatment in this insightful podcast episode at GU ASCO 2026. Featuring expert guests Dr. Chad Reichard, Dr. Shilpa Gupta, Dr. Matt Galsky, and Dr. Sia Daneshmand, the discussion covered the latest FDA-approved options for muscle-invasive bladder cancer (MIBC) and non-muscle-invasive bladder cancer (NMIBC), and exciting data that we are seeing presented at GU ASCO 2026. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 Follow us on social media: X/Twitter: https://twitter.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ In this episode, you'll learn about: The current treatment options for MIBC, including neoadjuvant Gem/Cis with perioperative durvalumab vs. EV/pembrolizumab combination Key findings from pivotal studies like KEYNOTE-905, NIAGARA, and KEYNOTE-B15 The implications of these studies on clinical practice and patient management The importance of a multidisciplinary approach in treating bladder cancer Emerging data on BCG plus immunotherapy combinations for NMIBC and their potential impact on treatment protocols Tune in for a comprehensive discussion that highlights the importance of collaboration between medical oncologists and urologists in optimizing patient care. Don't forget to like, subscribe, and hit the notification bell for more episodes from the Oncology Brothers! #BladderCancer, #MIBC, #NMIBC, #Immunotherapy, #EVpembro

RootsTech 2026 is over. There were so many great keynote speakers and classes. Brandon Isle takes a look back at the event, highlighting keynote speakers for the third day and BYU-Idaho-related interviews.

If you are watching the U.S./Israel military offensive against Iran and wondering about the safety of our men and women in uniform, safety here in the homeland, and what is most likely to come next in Iran, you are not alone. Decorated Middle East combat vet Colonel William "Burner" Dunn, USMC (Ret.), joins me to offer clear, operationally grounded analysis that stays relevant beyond today's headlines.Richard V. Battle, an award-winning, best-selling author, a generational influencing Keynote speaker and trainer for more than 30 years on topics including leadership, motivation, sales, and faith, and a media commentator frequently appearing on radio and television, joins me to discuss the Texas primaries, the Austin, Texas shooting (the shooting itself and both the media and FBI response), and the leadership secrets of Old McDonald. Col. William "Burner" DunnGunfighters Rule!Richard V. BattleAmeriCANS Who Made America ‐ 19th Century: Growth, Division, and ReunificationBecome a supporter of Tapp into the Truth: https://www.spreaker.com/podcast/tapp-into-the-truth--556114/support Tapp into the Truth on Rumble. Follow, watch the older shows, and join the live streams.Aimee's Audios Subliminal Acoustic Fingerprinting“Remember Pop Rocks? Now, imagine they gave you superpowers.” Please let me introduce you to Energy Rocks! Born from the grit and ambition of a competitive athlete who wanted a better, cleaner way to fuel the body and mind, without the hassle of mixing powders, messy bottles, or caffeine crashes. Energy Rocks is a reimagining of energy into something fun, functional, and fantastically effective. A delicious popping candy energy supplement that delivers a rapid boost of clean energy and focus — anytime, anywhere. No water. No mixing. No bulky bottles. Just open, pop it in your mouth, and get ready to rock. Making any time the right time to “Get in the Zone, One Pop at a Time.”Take This Free Quiz To Find Out The Best & Worst Foods To Avoid For Joint Pain!Do you wake up in the morning with stiff joints or pain in your hips, back, knees, or elbows? Then, chances are you're feeling the effects of chronic inflammation taking its toll on your body. The good news is that it is NEVER too late to help get this under control. And the best part is certain foods help you do this naturally, without the need for prescription medications.If recent events have proven anything, you need to be as prepared as possible for when things go sideways. You certainly can't count on the government for help. True liberty requires self-reliance. My Patriot SupplySupport American jobs! Support the show! Get great products at great prices! Go to My Pillow and use promo code TAPP to save! Visit Patriot Mobile or Call (817) 380-9081 to take advantage of a FREE Month of service when you switch using promo code TAPP! Morning Kick is a revolutionary new daily drink from Roundhouse Provisions that combines ultra-potent greens like spirulina and kale with probiotics, prebiotics, collagen, and even ashwagandha. Just mix with water, stir, and enjoy!Follow Tapp into the Truth on Locals Follow Tapp into the Truth on SubstackHero SoapPatriot DepotBlue CoolersKoa CoffeeBrainMDDiamond CBDSauce Bae2nd SkullEinstokBeanstoxBelle IsleHoneyFund"Homegrown" Boone's BourbonBlackout Coffee Co.Full Circle Brewing Co.Pasmosa Sangria  

AAHOA heads to Philadelphia for #AAHOACON26, and this year's theme stays dead simple: protect and advance profitability. Suzanne Bagnera, PhD, CHA, CED co-hosts #NOVacancyNews with me, and we talk with Laura Lee Blake (President & CEO, AAHOA) about what she wants owners focused on right now—and why this conference keeps growing. 

Welcome to the Oncology Brothers podcast! In this episode we continue our series on breast cancer treatment algorithms, focusing specifically on triple negative breast cancer (TNBC). We welcomed Dr. Tiffany Traina, a breast medical oncologist from the Memorial Sloan Kettering Cancer Center, to discuss the latest advancements in the management of TNBC. We dived deep into the treatment algorithm for early-stage disease, including the criteria for adjuvant chemotherapy, the use of neoadjuvant therapies like KEYNOTE-522, and the importance of balancing risk and benefit in treatment decisions. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Key topics covered in this episode included: * Criteria for adjuvant chemotherapy in early-stage TNBC * The role of pembrolizumab in neoadjuvant and adjuvant settings * Management of residual disease with capecitabine and olaparib * Insights into the latest clinical trials, including ASCENT-03, ASCENT-04, and TROPION-Breast02 * Side effect management strategies for new therapies Don't forget to subscribe for more episodes in our breast cancer series, and feel free to send us your questions and cases! Listen now and stay informed on the evolving landscape of triple negative breast cancer treatment! #TripleNegativeBreastCancer, #TNBC, #Pembrolizumab, #ADC, #OncologyBrothers

Dr. Monty Pal and Dr. Andrea Apolo discuss practice-changing studies and other novel approaches in bladder, kidney, and prostate cancers that were presented at the 2026 ASCO Genitourinary Cancers Symposium. TRANSCRIPT Dr. Monty Pal: Hello and welcome to the ASCO Daily News Podcast. I'm your host, Dr. Monty Pal. I'm a medical oncologist, professor and vice chair of academic affairs at the City of Hope Comprehensive Cancer Center in Los Angeles.  And today is super exciting, we're highlighting key abstracts that were presented at the 2026 ASCO GU Cancers Symposium, and I'm just delighted to be joined by the chair of this year's meeting, who is also a dear friend, Dr. Andrea Apolo. Dr. Apolo serves within the Center for Cancer Research at the NCI as head of the Bladder Cancer Section, and she is also acting deputy chief of the Genitourinary Malignancies Branch.  Welcome, Andrea, it is so great to have you on the podcast. Dr. Andrea Apolo: Oh, thank you so much for having me. What a great ASCO that we had, it is really exciting, lots of really great data. So I look forward to chatting about it. Dr. Monty Pal: Excellent. And you know, our full disclosures are available in the transcript of this episode in case our listeners want to have a peek.  The theme of this year's GU meeting was "Patient-Centered Care: From Discovery to Delivery." I love that theme. And really, this is one of the most competitive meetings out there, more than 850 abstracts being presented on high-impact science. Andrea, I just wanted to get right into it and dive into what I think we both felt were some of the most exciting abstracts of the meeting.  And the first of those is one that I know is near and dear to your heart, being a bladder cancer expert yourself, and that is the KEYNOTE-B15 study presented by Matt Galsky. Can you give us a flavor for what that study entailed and some of the key results? Dr. Andrea Apolo: Yeah, I think this was kind of the missing study that we have been waiting for since we saw the EV-302 data in metastatic disease in the frontline setting. We wanted to know how well this combination would work in muscle-invasive bladder cancer patients. And we saw half of that puzzle, you can say half of the piece of the puzzle, when we saw the data at ESMO, the EV-303 data in patients that were cisplatin-ineligible. And then now we are getting the full story with patients that are platinum-eligible, cisplatin-eligible, with the EV-304 data. So that study randomized patients to receive chemotherapy, so different than the EV-303 where the patients were randomized just to receive the radical cystectomy. These patients were randomized to receive neoadjuvant EV plus pembro and then adjuvant EV plus pembro versus neoadjuvant gemcitabine and cisplatin with no adjuvant component to the control arm. So I think this is a really, really important study. Dr. Monty Pal: And share with us some of the results because this in my mind is definitely practice-changing. This is one of those studies that I think you walked into the office on Monday and you are like, "Okay, this is what I am doing now," right? Dr. Andrea Apolo: Yeah. So the study was positive. The primary endpoint was event-free survival, and it met the primary endpoint. The secondary endpoint of overall survival was also met. So really, really great results. Consistent with what we saw with EV-303, the median event-free survival was not reached for the EV plus pembro arm, and it was 48 months for the patients receiving gem-cis. And then looking at the 24-month estimated event-free survival, it was 79% for the EV plus pembro and 66% for the chemo, the gem-cis arm. And that was a hazard ratio of 0.5. So that is really exciting. That is the event-free survival. And then the overall survival, the medians were not reached for either arm, but when you look at the 24-month estimated overall survival, it was 87% for the EV plus pembro versus 81% for the gem-cis, and that was a hazard ratio of 0.65. So very positive study.  And then another question that we had was the pathologic CR rate. Very consistent with what we saw with the EV-303, the pathologic response rate was about 56% for the patients that received EV plus pembro and about 32%, 33% for the patients that received gem-cis. So very consistent with the findings that we have been kind of seeing in phase 2 studies, and this is a pT0N0, so that is important. Dr. Monty Pal: So Andrea, you know, I think that the big question in folks' minds is at this point, we see the data from NIAGARA, cis-gem-durva, we have now seen this data. Put it into context for us. Is there a patient in this day and age who maybe shouldn't get IO altogether, who should maybe get the NIAGARA regimen as opposed to EV-pembro in this context? What are your thoughts there? Dr. Andrea Apolo: Now, that is a great question. I would say with this data, it is very enticing to give EV pembro to our patients in the perioperative setting, and for that to be the new standard of care for all patients, regardless of cisplatin eligibility. So similar to what we saw with EV-302 really changing the standard of care in the frontline setting, I think these two studies, the EV-303 and the EV-304, change the standard of care for patients with muscle-invasive bladder cancer in the perioperative setting, and this should be the new standard of care if the patients don't have a restriction to receiving an immunotherapy. Dr. Monty Pal: I totally agree with that assessment. It is great to hear it from the expert's mouth as well. Thanks a lot for that, Andrea.  The next abstract I wanted to tackle is one that is, I would say, near and dear to my heart because I know these folks really well. It is led by the SWOG group, and this is SWOG S1602. The number there for the audience gives you a sense of how long the study has been running for. The 16 prefix means it is something that we kicked off back in 2016. So this study is really 10 years in the making, right? So Rob Svatek presented this data. It is interesting, right, because it addresses this issue of the BCG (Bacille Calmette-Guérin) shortage, right, where we have needed to sort of rely potentially on other alternative sources or regimens and so forth. Tell us about this trial, Andrea. Dr. Andrea Apolo: This is one of my favorite studies. We talked about putting it in the main oral abstracts, but we put it in one of the educational sessions that talked about non-muscle-invasive bladder cancer because we thought that would be the best audience for it. But it doesn't take away from how important this abstract is, and the tremendous effort that went into the study. Almost a thousand patients enrolled. I think 984 were eligible to enroll in this study. So it is a very high enrolling, randomized, cooperative group study in high-grade non-muscle-invasive bladder cancer. And really the study was designed to address two questions. One is the BCG shortage and can we use a different strain, Tokyo versus TICE? And whether there is a priming effect if you gave intradermal BCG to patients with non-muscle-invasive bladder cancer, can that enhance the effect if you gave it a little bit earlier? I think the study is really important, and it met its primary endpoint, which was it is not inferior to TICE. The findings were really terrific in terms of the outcomes. Numerically. When you look at the endpoint, it looked like the Tokyo strain was as good, if not maybe a little bit better, but not statistically significant than the TICE. And then they broke it down by carcinoma in situ, they broke it down by papillary tumors, and the Tokyo strain was non-inferior in both of those instances. But interestingly, the intradermal BCG did not change outcomes. There was really no priming effect, which was really backed up by pre-clinical data that there would be, but there wasn't a priming effect when the intradermal BCG was given in the Tokyo strain. So that was a really, really interesting finding. But a great study, really important outcomes in the field for non-muscle-invasive bladder cancer. Dr. Monty Pal: Totally. And it just seems like we can't get away from BCG, right? You know, as hard as we try, I mean, I appreciate the studies that sort of build on it that are emerging right now, but it seems like BCG at least for the foreseeable future is kind of here to stay, right? Dr. Andrea Apolo: It works. It is one of the most effective treatments we have for non-muscle-invasive bladder cancer. So, you know, I think it is here to stay and, you know, we need to find alternatives in terms of strains so we don't deal with this shortage that we have been dealing with for so many years now. Dr. Monty Pal: Yeah, indeed. Moving on to some of the other highlighted studies from the meeting, you had mentioned the EV-303 data, so we probably don't need to rehash that study design in much detail. But there was also a rapid oral abstract presented by Dr. Ullén that I think is of interest here, right, that really hones in on pathologic outcomes and DFS from that trial. Do you mind just outlining that for our listenership? Dr. Andrea Apolo: This is the KEYNOTE-905, also known as the EV-303 study. This is a follow-up to the EV-303 data looking at the pathologic response rates, looking at the downstaging effect, looking at the surgical margins after treatment with the neoadjuvant EV plus pembro in the 303. Now, remember in the 303, patients got three cycles of neoadjuvant EV plus pembro and then six cycles in the adjuvant setting. A little bit different than the 304, where they got four cycles, which is really kind of the standard in the neoadjuvant setting, and then five cycles in the adjuvant setting. So still a total of nine cycles. But in the 303, the treatment arm had no systemic therapy, so it was just radical cystectomy. And they looked at the negative margins that you get with the EV plus pembro treatment, which was 92.6% versus 79% with patients receiving just the surgery alone. And then the pathologic CR rate, there was more follow-up on that, it was 57% for the patients receiving EV plus pembro, and as we would expect, about 9% for the patients that just went on to surgery alone because you can achieve a pathologic response rate with TURBT alone. Then they looked at the pathologic downstaging, so anything less than a pT2, and that was 66% in the patients that received the EV plus pembro. So very interesting findings, and it is also really just nice to have now the EV-304 data, like I was saying, there were two pieces of it, the cisplatin-eligible and the cisplatin-ineligible, and just to have those contemporary controls are really important. How did the cisplatin-ineligible do versus the cisplatin-eligible patient in terms of the event-free survival and in terms of the overall survival? So I feel like now we have all of this data that we can kind of put together in the perioperative setting and we can really inform our patients a little bit more about their outcomes depending on whether they are cisplatin-eligible or not, which you know cisplatin-ineligible patients often just, they are sicker, they may have obstruction, their tumors may be larger, they just tend to be a more delicate population than the cisplatin-eligible patients. So not surprisingly, you know, we see that in the EV-303 the disease-free survival for the patients is pretty poor. So the disease-free survival that was reported for this follow-up of the specific abstract was 23.6 months for the patients that just got surgery, and it was not reached for the patients that had the EV plus pembro, and that was a hazard ratio of 0.37. Dr. Monty Pal: Excellent, excellent distillation. So Andrea, in the interest of time, I mean, we could probably talk about bladder cancer forever, but I am going to move us on to the subject of kidney cancer. We have two late-breaking abstracts, LITESPARK-011, which looked at lenvatinib and belzutifan versus cabozantinib in the advanced setting, and then we have an adjuvant study, LITESPARK-022, that looked at pembrolizumab with or without belzutifan in the adjuvant setting. Both studies positive. One for progression-free survival, the other for disease-free survival. Both I think making a big dent in how we treat kidney cancer. Can you tell us a little bit about that? Dr. Andrea Apolo: Yeah, we have been waiting for these trials for a long time. So one of the things that we have been talking about at GU ASCO is to have plenary sessions. And if we would have had a plenary session, these two abstracts would have been part of it because they are important data, really big studies where we are trying to improve the outcomes of our patients with kidney cancer. So the first one, the LITESPARK-011, like you said, this is for advanced renal cell carcinoma, clear cell renal cell carcinoma, where we really don't have a standard of care after IO therapy, right? So we give IO-IO, we give VEGF-IO, but we don't really have a good standard of care. We usually give monotherapy TKIs. So the combination of belzutifan and lenvatinib versus what a standard of care is, cabozantinib, is really an important question to ask. And you know, this is a pretty large study, about 750 patients were randomized. And belzutifan plus lenvatinib demonstrated an improvement in progression-free survival and overall survival versus cabozantinib, but not overall survival, at least not yet, is what the authors are saying. So for the progression-free survival, the hazard ratio was 0.7 and it was 14.8 months for the combination, belzutifan plus lenvatinib arm versus cabozantinib, which was 10.7 months. So I think that is significant. And for the overall survival, it did favor the combination again with a hazard ratio of 0.85. The median was 35 months versus 28 months for the monotherapy cabozantinib, but it did not reach statistical significance. And the authors said that this will be further tested at a final analysis, these were the interim results.  And for the overall survival, the overall survival was 53% for the combination versus 40%. This is significant. And the CR rates were lowish for both of them, it was like 5% for the combo and 1% for cabo monotherapy. So I think that the findings are important because we don't have a standard of care. And although there is no survival benefit, there was a trend. So I think this could be considered in patients that are fit, a treatment option for these patients in the later line settings. Dr. Monty Pal: Great points. I mean lots of great discussion around toxicity as well as efficacy. I mean certainly this is a regimen that may not be suitable for every patient in my portfolio, but certainly one to consider.  Now Andrea, let's shift focus to LITESPARK-022, the adjuvant trial that I mentioned previously. So this is again looking at pembrolizumab with or without belzutifan, met the primary endpoint of disease-free survival. What are your impressions there of the data? Dr. Andrea Apolo: Yeah, the data looks great. And this was a really large study, 1,800 patients were randomized, and the study met the primary endpoint of disease-free survival, benefiting the combination of pembro plus belzutifan. And that is really terrific. The medians were not reached for either arm. And in terms of the overall survival results, also the medians were not reached, but the hazard ratio was 0.78 and did not reach a statistical significance. So there was again a statistically significant improvement in disease-free survival for the combination of pembrolizumab plus belzutifan, but not an overall survival benefit.  So I guess, Monty, you know, we can kind of talk about what that means. There was a lot of discussion about belzutifan and some of the side effects, specifically anemia and managing anemia in this setting and requirements for transfusions. Generally, the authors said it was well tolerated, but we know that combination studies do have more toxicity. So it may be a select group of patients again, similar to the advanced setting, where we opt for a combination, possibly until we see more follow-up data in terms of the overall survival. Dr. Monty Pal: I have to agree with you. You know, in my group, we have been talking about a lot of pembrolizumab-based studies that are running right now, some through the NCI, some, you know, our own sort of homegrown investigator-sponsored trials, and you know, I think for the foreseeable future we are comfortable just maintaining pembrolizumab. Things might change if, for instance, we ultimately see a survival advantage emerge, but I just have my own personal doubts around that, that will be interesting.  Okay, so now we are going to move to the last disease category that we are going to cover, which is prostate cancer. So there, we have the long-awaited results from the PEACE-3 study. These are the final OS results from this trial looking at enzalutamide with or without radium-223 in metastatic castration-resistant prostate cancer. So Andrea, would love to get your perspectives on this. Dr. Andrea Apolo: Yeah, so this study had been presented before and we had seen positive results for the combination of enzalutamide and radium with some interim overall survival results also showing a benefit. But like you said, these are the final results with a median follow-up of 58 months. So it was really nice to see the final results. And with the combination of enzalutamide and six cycles of radium, it did show an improvement in overall survival with a hazard ratio of 0.76. The median overall survival increased from 32.6 months to 38.2 months with the combination. So that is really great. There was some crossing over of the overall survival curves around 18 months was still seen. And again, there was also an improvement in the rPFS with a hazard ratio of 0.71, and the median rPFS improved from 16.4 to 19 months with the combination. So, you know, we have been awaiting the final results, but we kind of knew a lot about the benefits of the combination. And it is something that is kind of slowly trickling into the community in terms of adapting it and using it. There is more buzz now about it and I think these overall survival results will hopefully shift the community into incorporating the combination in these patients. Dr. Monty Pal: Brilliant. So well said. I mean, Andrea, congratulations on a terrific meeting. You have really done it again. Incredible, incredible output from this year's ASCO GU. I just want to thank you for joining us on the program today. Dr. Andrea Apolo: Oh, thank you so much for having me, Monty. It was really a joy to work with the ASCO team and with all the investigators and the Education Committee and the Scientific Committee. Everyone was really outstanding. So to me it was an honor to be part of this meeting, and I am so happy that it was so successful and really presented some amazing data that I think will be practice-changing to our patients. Dr. Monty Pal: Oh, thanks a ton. And also a huge thanks to our listeners. If you enjoyed the content of today's podcast, please don't forget to like and subscribe to our channel wherever you listen to podcasts. Thanks so much. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:     Dr. Monty Pal   @montypal  Dr. Andrea Apolo @apolo_andrea  Follow ASCO on social media:          ASCO on X    ASCO on Bluesky         ASCO on Facebook          ASCO on LinkedIn          Disclosures:       Dr. Monty Pal:      Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview     Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical     Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis     Dr. Andrea Apolo: No disclosures to report.

Dans un marché crypto où près de 85 % des nouveaux tokens finissent par s'effondrer, comment identifier les vrais projets qui créent de la valeur ? Pourquoi l'écosystème crypto évolue vers des modèles générateurs de revenus réels ? Cyrus nous explique cela et revient sur comment investir plus intelligemment en comprenant le spread, un indicateur souvent bien plus déterminant que les simples frais de trading pour optimiser vos performances.Enfin, plongez dans les dernières innovations de SwissBorg : carte bancaire, cashback, trigger orders, retraits protégés...Poscast réalisé en collaboration commerciale avec SwissBorg.

In this special keynote spotlight episode of Problem Solved, IISE's Frank Reddy sits down with Dr. Mark Benden, researcher, inventor of nearly 30 patents, and longtime leader in ergonomics innovation. With more than four decades of experience across military service, industry, and academia, Dr. Benden has helped generate over $2.5 billion in economic impact through human-centered design and workplace innovation.In this conversation, he shares:How everyday frustration becomes inventionWhy “nuisance is the father of invention”How AI, motion capture, and wearables are transforming worker healthThe shift from injury response to real-time preventionAnd how to take ergonomic improvements from idea, to protection, to commercializationJoin us for this inside look at one of AEC's keynote voices. And don't miss Problem Solved LIVE on-site at AEC, where we'll be capturing insights from innovators shaping the future of ergonomics.Applied Ergonomics Conference sponsored by Applied Ergonomics SocietyLearn more about The Institute of Industrial and Systems Engineers (IISE)Problem Solved on LinkedInProblem Solved on YouTubeProblem Solved on InstagramProblem Solved on TikTokProblem Solved Executive Producer: Elizabeth GrimesInterested in contributing to the podcast or sponsoring an episode? Email egrimes@iise.org

In this episode, UROONCO BCa chief editor Dr Benjamin Pradere (France) sits down with Matthew Galsky, Professor of Medicine at Icahn School of Medicine at Mount Sinai (New York, USA), to discuss the newly published results of the KEYNOTE-B15 trial.This marks a truly pivotal moment for muscle-invasive bladder cancer. The presentation of KEYNOTE-B15 represents one of the most practice-changing advances in localised MIBC management in recent years, opening a new era of peri-operative systemic therapy and renewed hope for our patients.KEYNOTE-B15 is a randomised phase III trial evaluating peri-operative enfortumab vedotin plus pembrolizumab in cisplatin-eligible patients with MIBC. In this in-depth discussion, Prof. Galsky walks us through the scientific rationale behind the study, the key efficacy and safety results, and crucially, how these data are likely to reshape clinical practice, not only in the immediate future but for years to come.A must-listen conversation for urologists and multidisciplinary teams involved in the care of bladder cancer patients.The KEYNOT-B15 study will be also presented and discussed at upcoming EAU26 on Saturday 14th March in the Game Changer Session. Don't miss the chance to hear more on this important study and mark your agenda! This interview was recorded at ASCO GU26. For more updates on bladder cancer, please visit our educational platform UROONCO BCa.For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.

In this podcast , Brian, Tom and Matt Galsky discuss the B15 study data on neoadjuvant therapy for muscle invasive bladder cancer, focusing on the efficacy of EV Pembro compared to gem-cis. They explore event-free survival, overall survival, and the implications of treatment duration and individualization. The conversation also touches on the role of ctDNA in treatment decisions, alternative histologies, and the importance of neoadjuvant systemic therapy. The hosts conclude with reflections on future directions in bladder cancer treatment and the significance of ongoing studies.

“We keep iterating on an old construct—let's stop and start over. How do we want to do things differently? Let's get back to first principles.”KP ReddyEpisode Summary:In this special ElevateAEC 2025 edition of The Zweig Letter Podcast, we're sharing KP Reddy's keynote from the main stage—a straight-talk session about where innovation in AEC is actually heading. Drawing from real conversations with major owners, hands-on research, and his own experience as an engineer and investor, KP breaks down why the industry's current approach to innovation isn't cutting it—and what needs to change.He tackles the questions that matter: What do owners actually want? How can AI and agentic systems make a real difference? And what would a new master builder mindset look like today? This keynote delivers practical insights and honest challenges for AEC leaders ready to rethink how they approach business, technology, and client value.Key Takeaways:Owners Want Real Innovation, Not Lip Service: True innovation means solving problems in significantly better ways—not just adopting new technology for technology's sake. Owners are craving AEC partners who listen and deliver true value.Communication Gaps Hurt Everyone: Clients frequently feel like outsiders in the process, with their feedback often ignored. Successful firms will prioritize transparency, owner-centric approaches, and collaborative requirement gathering.Tech Is a Tool—Not the Solution: Despite years of BIM and other advancements, core challenges with cost, schedule, and quality persist. The next leap forward will come from integrating AI, agentic design, and robotics as part of service delivery—and from business models, not software alone.Business Model Reinvention Is Essential: Shifting away from headcount-driven metrics, AEC firms should explore skin-in-the-game approaches—like bonuses for outcomes, equity stakes, and public-private partnerships.Client and Product Manufacturers Must Both Change: Building-product innovators report frustration as AEC professionals and owners often resist new solutions. KP encourages the industry to break the cycle of “the way we've always done it” and fully explore prefabrication, modularity, and automation.All this and more on this episode of the Zweig Letter podcast.KP Reddy is the founder and CEO of Shadow Ventures and a recognized voice on innovation in architecture, engineering, and construction. With expertise spanning AI, robotics, and automation—plus his role as a lecturer at Georgia Tech—KP brings practical strategies that push the AEC industry forward.Links referenced in this episode:Shadow VenturesKP Reddy on LinkedIn"Creating the Intangible Enterprise" by KP ReddyZweig Group & ElevateAEC ConferenceLearn about the Zweig Letter and subscribe: https://thezweigletter.com/Connect with Randy Wilburn on LinkedInGet your FREE Subscription to the Zweig Letter Newsletter.Stay tuned for more enlightening content from the Zweig Letter podcast, and make sure to subscribe for regular updates!Other episodes you'll enjoy:Architecture with Heart - Carley ChastainFrom Specs to Stories with Cherise LakesideBridging Design and Construction with Dan CristAI Transforming AEC with KP ReddyConnect with Zweig Group:Instagram: Zweig GroupFacebook: Zweig GroupTwitter: Zweig GroupLinkedIn: Zweig GroupWebsite: Zweig Group

Dr. Lakshmi Rajdev and Dr. Manish Shah join the podcast to discuss the updated guideline on immunotherapy and targeted therapy in unresectable locally advanced, advanced, or metastatic gastroesophageal cancer. They share first-line and subsequent-line recommendations for both gastroesophageal adenocarcinoma and esophageal squamous cell carcinoma based on actionable biomarkers including PD-L1 expression, MMR and/or MSI, CLDN18.2 expression, and HER2 status. They note the importance of the algorithms and tables in the guidelines that provide visual illustrations and quick reference guides of the evidence-based recommendations. They also comment on ongoing and recently presented trials that may impact future guidelines in this space. Read the full guideline, "Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline Update" at www.asco.org/gastrointestinal-cancer-guidelines" TRANSCRIPT This guideline, clinical tools and resources are available at www.asco.org/gastrointestinal-cancer-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology,  https://ascopubs.org/doi/10.1200/JCO-25-02958      Timestamps ·       00:00 – 02:15 Introduction and Overview ·       02:16 - 08:20 First-line treatment for patients with pMMR/MSS, HER2-negative gastroesophageal adenocarcinoma ·       08:21 –10:29 First-line treatment for patients with pMMR/MSS, HER2-positive gastroesophageal adenocarcinoma ·       10:30 – 14:39 First-line treatment for patients with dMMR/MSI-H, gastroesophageal adenocarcinoma ·       14:40 – 18:03 First-line treatment for ESCC ·       18:04 – 22:04 Second- and third-line therapy for gastroesophageal adenocarcinoma and ESCC ·       22:05 – 24:38 Importance of guideline ·       24:39 – 27:45 Outstanding questions and future research   Brittany Harvey: Hello and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges, and advances in oncology. You can find all the shows, including this one, at asco.org/podcasts.   My name is Brittany Harvey, and today I am interviewing Dr. Lakshmi Rajdev from the Icahn School of Medicine at Mount Sinai and Dr. Manish Shah from Weill Cornell Medicine, co-chairs on "Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline Update." Thank you for being here today, Dr. Rajdev and Dr. Shah. Dr. Lakshmi Rajdev: Thank you. Dr. Manish Shah: Thank you for having us. It is wonderful. Brittany Harvey: And then just before we discuss this guideline, I would like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO conflict of interest policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Rajdev and Dr. Shah, who have joined us here today, are available online with the publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes. So then to dive into what we are here today to talk about, Dr. Shah, I would like to start first with what prompted the update to this guideline, which was previously published in 2023, and what is the scope of this updated guideline? Dr. Manish Shah: Yes, terrific. So even in the last few years, the pace of drug development in gastroesophageal cancers has just been astounding. So, what prompted this guideline is actually the practice-changing results for a new biomarker, CLDN18.2 hat was based on the GLOW and SPOTLIGHT studies, as well as a practice-changing study in HER2-positive disease where we added pembrolizumab to trastuzumab and chemotherapy for tumors that are HER2-positive and PD-L1 CPS 1 or greater. And then there were also new studies and new approvals in esophageal squamous cell cancer that you will hear about as well. So there were several studies, overall more than 5,000 patients were reported on, and that led to several new therapies, new indications, and it really necessitated this guideline. Brittany Harvey: Excellent. It is great to hear about all of these exciting updates in this space. So then to next review the key recommendations of this guideline by clinical question that the expert panel addressed. So, Dr. Rajdev, what is the recommended first-line treatment for patients with proficient mismatch repair, microsatellite stable, HER2-negative gastroesophageal adenocarcinoma? Dr. Lakshmi Rajdev: Thank you for that question. So historically, we have sort of used fluoropyrimidine and platinum doublets, which yielded a survival of about one year. More recently, immunotherapy and targeted therapy options have improved outcomes in patients with advanced esophageal and gastric adenocarcinoma, as well as squamous cell carcinoma. Patients with gastric and GE junction adenocarcinoma have a high rate of actionable alterations, so it is imperative that physicians test the following biomarkers upfront so that it can help guide therapy. The markers recommended by the ASCO panel are HER2, MMR or MSI, CLDN18.2, and PD-L1. And also, it was recommended to use NGS if feasible in this patient population. HER2, as we know, is expressed in about 15% to 25% of patients; PD-L1 expression occurs in about 80% of patients; MSI-high, deficient MMR is present in about 5% to 8% of patients; and CLDN18.2 expression is present in about 40% of patients. There is, of course, biomarker overlap. About 13% to 22% of CLDN18.2 patients are also PD-L1 positive. For patients with pMMR or microsatellite stable HER2-negative disease with PD-L1 expression greater than 1 and absence of CLDN18.2, the panel recommended a first-line therapy with fluoropyrimidine and platinum-based therapy in combination with immunotherapy. These recommendations stem from large phase 3 trials, and the agents approved in the United States are pembrolizumab, nivolumab, and tislelizumab. It has been shown that immunotherapy benefit is greater in patients with higher PD-L1 expression, and it is not possible to comment on the individual PD-L1 cutoff scores and sort of identify the optimal PD-L1 cutoff score that sort of balances benefits and harms. But what is recommended is that immunotherapy-based treatments can be offered in patients with a CPS score of greater than 1. With regard to the choice of immunotherapy agents, that is pembrolizumab, nivolumab, or tislelizumab, these agents are considered to have similar efficacy, and the selection of an agent could be based on dosing schedule, cost considerations, toxicity, and the method of administration. Typically, clinicians should avoid withholding the start of chemotherapy while awaiting biomarker testing, depending on the clinical scenario. Now, for patients with pMMR microsatellite stable disease that is HER2-negative with PD-L1 expression less than 1 and positive CLDN18.2 expression, zolbetuximab-based treatments or in combination with chemotherapy is recommended, and this is based on two global phase III randomized controlled trials, the GLOW and the SPOTLIGHT. And across both studies, the hazard ratio for the overall survival was 0.78, and similarly, there was also an improvement in progression-free survival favoring the zolbetuximab group compared to the chemotherapy group alone. An important note is that nausea, vomiting is commonly associated with zolbetuximab-based treatments, and the panel recommended prophylactic antiemetics, adjusting zolbetuximab infusion rates, pausing infusion temporarily, using non-prophylactic antiemetics, and hydration intravenously prior to discontinuation of zolbetuximab-based chemotherapy. So effective handling of the GI-related symptoms with zolbetuximab is recommended prior to discontinuation of therapy. Now, for patients with pMMR microsatellite stable HER2-negative gastric, GE junction adenocarcinoma with PD-L1 expression greater than 1 and CLDN18.2 positivity, the ones with the dual expression with CLDN18.2 as well as PD-L1 chemotherapy, the choice of therapy can be based on the degree of PD-L1 expression, the toxicity profile, the burden of symptoms, and the anticipated improvement in symptoms associated with response to treatment, the patient comorbidities, the prior medical and treatment history. So this decision needs to be made on a case-by-case basis, and these are some of the factors that we suggested that could potentially influence the choice of therapy. For patients with pMMR microsatellite stable disease that is HER2-negative and a PD-L1 expression less than 1 and an absence of CLDN18.2 expression, first-line therapy with fluoropyrimidine and platinum-based chemotherapy is recommended. So you can see we have segmented out patients based on PD-L1 expression, pMMR and microsatellite stable disease expression, and also based on CLDN expression. Brittany Harvey: Absolutely. And that first point you noted, I think is really important, that biomarker testing is really critical for treatment decision-making in this space. So then the next subgroup of patients that the panel looked at, Dr. Shah, what first-line therapy is recommended for patients with proficient mismatch repair, microsatellite stable, HER2-positive gastroesophageal adenocarcinoma? Dr. Manish Shah: So this was an update from a few years ago. So we have known for 15 years now that if you are HER2-positive, you should get trastuzumab plus chemotherapy. That was based on the ToGA trial. And the update now is based on a trial called KEYNOTE-811, where it examined the addition of pembrolizumab to trastuzumab and chemotherapy versus trastuzumab and chemotherapy, and there was a progression-free and overall survival benefit. And again, here, the biomarkers are important. If your CPS PD-L1 is less than 1, we would not recommend Pembrolizumab in that setting, so you would still get trastuzumab and chemotherapy. But if it is 1 or greater, the PD-L1 CPS score, then we do recommend pembrolizumab unless there is a contraindication to immunotherapy. The take-home message really is from the onset of diagnosis, please check your biomarkers. And I will just, it is worth repeating, it is important to check your PD-L1 status, HER2 status, mismatch repair status, and CLDN18.2 status. And then the optimal therapy, and it is outlined in the publication, is really biomarker-driven. We know that if we are able to hit the target that is overexpressed, we are going to have a better outcome. And Dr. Rajdev did mention where there is overlap, there can be a lack of data, and that is where we are with both PD-L1 positive and CLDN positive. Here we do have data in HER2-positive cases where if you are both HER2-positive and PD-L1 positive, you would combine trastuzumab and pembrolizumab for the best outcomes. Brittany Harvey: Understood. I really appreciate you detailing what is most important for each individual biomarker combination that patients may have. So then following that, Dr. Rajdev, what does the expert panel recommend for first-line treatment for patients with esophageal squamous cell carcinoma that is not amenable to definitive chemoradiation? Dr. Lakshmi Rajdev: There are three phase III randomized clinical trials that have influenced practice in patients with esophageal squamous cell carcinoma examining the benefit of immunotherapy in this patient population. The RATIONALE-306 was a randomized trial of tislelizumab plus chemotherapy with platinum and fluoropyrimidine or paclitaxel versus placebo with chemotherapy. And then you have the KEYNOTE-590, which compared pembrolizumab plus chemotherapy versus chemotherapy alone. And then you have CheckMate-648, which included comparisons of nivolumab plus chemotherapy versus nivolumab plus ipilimumab or chemotherapy. And the primary endpoints for these studies were overall survival, and they did look at subgroups with PD-L1 expression. They used TPS score greater than 1% in CheckMate-648 and PD-L1 CPS greater than 10 in KEYNOTE-590. The bottom line is that the overall hazard ratio for overall survival across this patient population was 0.72. So clearly, there is benefit in patients that express PD-L1 CPS greater than 1 for benefit for the addition of immunotherapy. Now, the benefit again in patients with a PD-L1 expression less than 1 remains limited, and so the panel has made a recommendation for using immunotherapy in combination with platinum-based chemotherapy in patients with a PD-L1 greater than 1. Again, we know that it is hard to make recommendations on what PD-L1 cutoffs are recommended in this patient population, meaning that should it be limited to patients with a PD-L1 of 1 to 4 or greater than 10? I think that the general consensus that has been gleaned from the data is that the higher the PD-L1 expression, the greater the benefit. I do want to comment on another option that is available in patients with squamous cell carcinoma compared to adenocarcinoma, and that is the combination of nivolumab and ipilimumab. Now, in CheckMate-648, nivolumab with ipilimumab was also recommended as a treatment option in patients that have a PD-L1 score of greater than 1. There was a survival benefit demonstrated with this combination compared to chemotherapy alone. And an important observation in this study is that, although there was a slightly increased rate in early death, but there was really no significant difference in PFS and OS compared to chemotherapy alone. Importantly, the treatment appeared to be pretty well tolerated by the study population. There was a notable difference in the objective response rate, which was 35% in the nivolumab plus ipilimumab group compared to patients receiving nivolumab and chemotherapy, where it was 53%. So superiority is, so the importance of chemotherapy in patients with esophageal squamous cell carcinoma is to be noted. However, there is no difference in overall survival and progression-free survival when using the combination of nivolumab and ipilimumab, and thus it affords a chemotherapy-free option for this patient population with esophageal squamous cell carcinoma and a CPS with a score of greater than 1. Brittany Harvey: Understood. I appreciate you reviewing the evidence underpinning those recommendations as well. So then the next patient population that the guideline panel addressed, what first-line therapy is recommended for patients with deficient mismatch repair, microsatellite instability-high, gastroesophageal adenocarcinoma or esophageal squamous cell carcinoma? Dr. Lakshmi Rajdev: The rate of MSI-high expression is about 3% to 7% across different studies. Now, the KEYNOTE-158 was a tumor-agnostic study in patients with non-colorectal cancers, and again, the problem with the MSI-high population, given that it is so rare, the numbers in the individual studies are fairly small. But consistent outcomes do emerge, indicating high response to immunotherapy. So in KEYNOTE-158, a response rate of about 46% was noted. The number of patients was small, it was about 24. In CheckMate-649, which is a study of chemotherapy plus or minus nivolumab in patients with advanced gastric adenocarcinoma, there was again a very small number of patients, and patients that were MSI-high or deficient MMR did experience substantial benefits with the addition of immunotherapy, with hazard ratios in the order of about 0.38. In KEYNOTE-062, again, it was a very small number of patients, again about 6% or so, and similar to CheckMate-649, a substantial benefit was noted in combination with chemotherapy, but also there were benefits noted with pembrolizumab alone. The RATIONALE-305 again was a study of tislelizumab in combination with chemotherapy and similarly showed benefits to the combination of chemotherapy plus immunotherapy in this patient population. I think that we are all aware of the dramatic benefits of immunotherapy in this particular subset of patients, deficient MMR MSI-high, and also we have seen in CheckMate-649 they did have a subset of patients that received nivolumab and ipilimumab. And in this patient population, they noted unstratified hazard ratio of 0.28. So I think that the overall consensus is that immunotherapy is a very important treatment modality in patients with deficient MMR MSI-high disease, given that a lot of the trials in gastroesophageal adenocarcinoma have utilized chemotherapy-based options, that is certainly a recommendation of the panel to use chemotherapy in combination with immunotherapy. However, on a case-by-case basis, the panel recommended immunotherapy alone as well, and given the high response rates noted in trials across different diseases as well as noted in this disease as well. Brittany Harvey: Certainly. And I appreciate you both for reviewing these first-line recommendations. So moving to later lines of therapy, Dr. Rajdev, what recommendations did the expert panel make for second or third-line therapy for gastroesophageal adenocarcinoma and esophageal squamous cell carcinoma? Dr. Lakshmi Rajdev: So, I think that the RAINBOW trial that investigated the utility of the addition of ramucirumab as second-line therapy has been around since 2014, and those results have led to the addition of ramucirumab to taxane-based therapy in the second-line setting. Based on the utilization of oxaliplatin and platinum-based therapy in the front-line setting, there may be patients that have an underlying neuropathy, and so we wanted to really include treatment options for this patient population so that an agent that is less neurotoxic could also be recommended in combination with ramucirumab. The RAMIRIS trial is one such trial where ramucirumab was combined with FOLFIRI, and it demonstrated benefit in combination with ramucirumab. So we have listed that as a potential treatment option for patients in the second-line setting who may have an underlying neuropathy or even for whatever reason that based on the toxicity profile, that needs to be the preferred option by a physician, that recommendation is new from the older guidelines that we have. With regard to the utility of PD-1 inhibitors, there really has been no benefit noted in the second-line setting with regard to overall survival or progression-free survival, so no recommendation is made for that option. I think an important study that has been recently presented is the DESTINY-Gastric04 trial, which really has been practice-changing and has led to the recommendation for trastuzumab deruxtecan in patients that have HER2-positive metastatic gastric or GE junction adenocarcinoma. Now, this is a phase III trial in patients who retained HER2-positive disease after progressing on front-line trastuzumab-based treatments, and the comparator for this trial was trastuzumab deruxtecan versus ramucirumab plus paclitaxel. There was significant improvement and progression-free survival in patients that received trastuzumab deruxtecan. The patients that were excluded from the trial are patients that have pulmonary problems, interstitial lung disease; that is one of the toxicities of this particular agent, and close monitoring and prompt initiation of therapy such as glucocorticoid treatment in patients who develop this toxicity was also highlighted by the panel. So to summarize, the new guidelines highlight the possibility of FOLFIRI plus ramucirumab as a second-line option and then trastuzumab deruxtecan as a later-line option in patients that still retain HER2 expression. And that is very important because the trial did retest patients whether they expressed HER2. As we know, in a substantial number of patients, there is downregulation of HER2, and there is emerging data that the benefit for subsequent HER2-directed therapies is best noted in patients that still retain HER2 expression. Brittany Harvey: Great. So as our listeners have heard, there are many recommendations and new treatment options for advanced gastroesophageal cancer. Dr. Shah, earlier you highlighted the importance of biomarker testing, but I would like to hear in your view, what is the importance of this guideline and how will it impact both clinicians and patients with gastroesophageal carcinoma? Dr. Manish Shah: So as we have discussed throughout this podcast, the treatment for gastroesophageal cancer, both adenocarcinoma and squamous cell cancer, is increasingly complex, increasingly biomarker-driven. And I think the value of the guideline is to place all of that into context. So it provides the data for why certain biomarkers are important, what therapies should be indicated. Not only that, but if you are able to review the guideline, it provides the details of each of these studies and summarizes them in a meta-analysis fashion to sort of give you the context, because sometimes the individual studies can be maybe a little bit discordant or confusing and the guideline attempts to harmonize all that. And then also, I think the tables are very, very interesting because they give you actual numbers in terms of how many patients over a thousand would this benefit or how many patients over a thousand would this cause harm in terms of nausea, vomiting, or other things like that. So it gives you context for helping clinicians and patients weigh the potential benefits of the novel treatment strategies against the potential adverse events. And then finally, the guideline does also provide an algorithm that you are able to follow based on the biomarkers, and those are in figures 4 and 5. So I think overall, it is a very comprehensive guideline. It intends to make more manageable a very complex subject, and you know, I really encourage our listeners to review it after listening to the podcast. Dr. Lakshmi Rajdev: If I can add to that, I think that what is also really good about the guidelines is there are quick summaries. So if someone is busy in the clinic, of course, there is the opportunity to review the data supporting the guidelines in great depth in the manuscript, but what is also really good is that there are good summaries. In the event that you are very busy, you can easily identify what the recommendations should be for that particular patient based on these summaries. Brittany Harvey: Absolutely. Listeners are encouraged to review the full guideline, including those tables and figures that may be more helpful when they are looking for something quick to look at in the clinic as well. So, as you both mentioned, there have been a number of recent practice-changing trials in this area. So I imagine there is still a lot of ongoing research as well. So Dr. Shah, what are the outstanding questions regarding treatment options for patients with locally advanced unresectable, advanced, or metastatic gastroesophageal carcinoma? Dr. Manish Shah: I think we touched upon it a little bit. The guidelines are based on the data available, and they are primarily examining one novel therapy with chemotherapy in a specific biomarker population. But as you know, the biomarkers are not either/or; you are not either CLDN18.2 positive or PD-L1 positive. A portion of patients could have dual biomarkers, and you know, I think that we are generating data on how to manage those patients. At the recent GI Symposium in January this year, the ILUSTRO trial was presented by Dr. Shitara, which looked at combining zolbetuximab and chemotherapy with immunotherapy for dual-positive biomarkers, and that is leading to a phase III study that has begun to enroll. So unanswered questions are: how do we manage dual-positive biomarkers? The other thing that was mentioned is that the current data for mismatch repair deficiency involve chemotherapy plus immunotherapy. Only squamous cell cancer is there a study with a positive non-chemotherapy kind of backbone, that is CheckMate-648 that Dr. Rajdev mentioned. As we move forward, it will be good to get data on non-chemotherapy options in certain biomarker-positive populations. And then finally, another update, which is likely to be practice-changing, is the HERIZON-GEA-01 study that looked at zanidatamab, which is another biparatopic antibody that targets HER2, and that is likely to change practice. And as that data gets published, we may look to even do a rapid update for the current immunotherapy and targeted therapy guideline that is just being published. Dr. Lakshmi Rajdev: So, if I can add to that, there are numerous ADCs that look very interesting. There are bispecific antibodies; in fact, the zanidatamab is a bispecific antibody showing improved activity in patients with HER2-positive disease. So I think there are studies from Asia looking at CLDN CAR T-based therapies. So, I think that there are a lot of novel agents and a lot of excitement in the field. We know that the bemarituzumab study, unfortunately, the FGFR2 inhibitor failed to demonstrate any benefit, but I think that there are other agents that are being explored, so there are newer targets, newer agents, ADCs, bispecifics that could potentially change the field in the future. Brittany Harvey: Yes, we will look forward to the data to address these unanswered questions and new agents and inform future guideline updates. So, I would like to thank you both for all of your work to review the evidence here and update this important guideline, and for your time today, Dr. Rajdev and Dr. Shah. Dr. Lakshmi Rajdev: Thank you. Dr. Manish Shah: Thank you. Brittany Harvey: And finally, thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the full guideline, go to www.asco.org/gastrointestinal-cancer-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app, which is available in the Apple App Store or the Google Play Store. If you have enjoyed what you have heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

In dieser Episode von Kassenzone, moderiert von Karo und Alex, nehmen wir die Zuhörer mit auf eine spannende Reise durch die aktuellen Entwicklungen im E-Commerce-Sektor. Wir reflektieren über die ersten Events des Jahres 2026, die für uns eine wichtige Plattform darstellen, um wertvolle Einblicke zu gewinnen und mit der Community zu interagieren. Besondere Erwähnung finden die Teilnahme an der E-Commerce Expo in Berlin, wo wir zahlreiche interessante Kontakte knüpfen konnten, sowie die hochkarätige Keynote von Alex, die großes Interesse weckte. Ein zentrales Thema dieser Episode ist das Kassenzone-Meetup, das sich heute mit dem TikTok-Shop auseinandersetzt. Alex gibt uns einen Einblick in die Fragen, die er den Experten bei diesem Event stellen möchte, und wir sprechen darüber, wie TikTok auch für hochpreisige Produkte ein funktionierender Vertriebskanal sein könnte. Neben dem Fokus auf die Community und den Austausch von Ideen in den Meetups, bereiten wir uns auch auf zukünftig große Events wie die OMR und Data Unplugged vor, bei denen wir die Möglichkeit haben, noch intensivere Gespräche zu führen und wertvolle Erkenntnisse zu gewinnen. Wir steigen dann tief in die neuesten Zahlen des ECDB Global E-Commerce Compass 2026 ein. Wir analysieren, wie das globale E-Commerce-Wachstum in den letzten Jahren eine Phase der Normalisierung durchläuft. Die Wachstumsprognosen deuten auf eine Stabilisierung bei 7,8 Prozent für 2025 und eine beschleunigte Rate von 8,6 Prozent für 2026 hin. Wir stellen fest, dass der weltweite E-Commerce-Umsatz die 5 Billionen US-Dollar-Marke überschreiten wird, was die nachhaltige Relevanz des Online-Handels im Vergleich zum analogen Einzelhandel unterstreicht. Partner in der Folge: https://linktr.ee/kassenzone Community: https://kassenzone.de/discord Feedback zum Podcast? Mail an alex@kassenzone.de Disclaimer: https://www.kassenzone.de/disclaimer/ Kassenzone” wird vermarktet von Podstars by OMR. Du möchtest in “Kassenzone” werben? Dann https://podstars.de/kontakt/?utm_source=podcast&utm_campaign=shownotes_kassenzone Alexander Graf: https://www.linkedin.com/in/alexandergraf/ https://twitter.com/supergraf Youtube: https://www.youtube.com/c/KassenzoneDe/ Blog: https://www.kassenzone.de/ E-Commerce Buch 2019: https://amzn.eu/d/5Adc1ZH Plattformbuch 2024: https://amzn.eu/d/1tAk82E

The global credit market is worth $300 trillion and Michael Saylor believes digital credit will capture a massive share of it. In this keynote from Strategy World 2026, Saylor walks through the complete theory of digital credit from first principles: what Bitcoin is, why variable preferred equity is the longest-duration capital structure short of equity, and how STRC delivers double-digit yields with deferred tax treatment and principal protection. He also lays out the programmable future of digital money and digital yield, with ETFs, on-chain tokens, and bank accounts all being built on top of STRC as a foundation.

Join host Anne Bonney, CSP, as she chats with Cassandra Worthy about her journey from corporate leader to main stage Influence speaker. Get straight talk on the strategies, mindset, and frameworks that can help you bring lasting value to your clients and grow your speaking business.What you'll learn in this episode:* How Cassandra Worthy transitioned from corporate America to a career in speaking* The pivotal moment that inspired her "change enthusiasm" framework* Why building a practical, actionable framework sets speakers apart* What clients are really looking for now—partnership over performanceTop advice for speakers preparing for big stages and growing their network strategicallyBecome an NSA Member! https://nsaspeaker.org/join/#membership Attend Influence 2026! Register here: https://influence.nsaspeaker.org/ Learn more about your ad choices. Visit megaphone.fm/adchoices

Presidential Task Force on Institutional Voice Draft Report  October 2025 Update  Please provide feedback on the report  Members of our community —  whether students, staff, faculty, or alumni — feel deeply about many local, national, and world events, but does that mean that a university should opine on such weighty matters? Or should the university sit back and allow the individual voices of the community rise to the surface? Can it do both? And when the university does speak, who speaks for the university? What principles should govern this decision of when and how often to speak?  Last year, Cornell University created the Presidential Task Force on Institutional Voice to examine these questions and issue recommendations to the community. A draft report was released to the Cornell community during the fall semester outlining principles and providing suggestions to guide how the president, provost, deans, academic departments, and others should approach this issue. The Task Force was co-chaired by Cornell Law School Dean Jens David Ohlin and Deputy Provost Avery August. In this Keynote, Dean Ohlin and the Professor Nelson Tebbe will discuss the Task Force's findings. What You'll Learn: How Cornell University is studying the issue of institutional voice The principles and guidelines recommended by Cornell's Presidential Task Force on Institutional Voice The various approaches that other universities have taken on this issue Follow eCornell on YouTube, Facebook, Instagram, LinkedIn, TikTok, and X.

In deze Deep Dive duiken we in de oude doos met Bart Mol van Satoshi Radio, het Crypto Journaal en Bitcoin Alpha. Hoe hebben de grote cryptoverhalen van vroeger de cryptowereld van nu gevormd? Om die vraag te beantwoorden kijken we terug naar de verwoede pogingen van de Winklevoss broers om een Bitcoin ETF uit te geven, de blockchainhype van 2017 toen alles en iedereen dacht dat blockchain de wereld ging veranderen en naar het Libra-project van Facebook. Ook de legendarische Bitconnect conferentie en de Terra/Luna Death Spiral passeren de revue. Alle verhalen vertellen iets over hoe we naar Bitcoin en crypto keken, hoe bedrijven en personen zich profileerden naar de buitenwereld en ook hoe het publiek omging met de hype die er soms rond crypto hangt. Sommige initiatieven strandden, andere inspireren bedrijven om bepalende stappen te maken die de wereld van het geld nog steeds vorm geven. We bespreken hypes, trends en alle te mooie beloftes van de afgelopen vijftien jaar in deze aflevering van de Deep Dive. Besproken in deze aflevering Keynote van Bart op Bitcoin Amsterdam Bart over de risico's van het 'Bitcoin als digitaal goud-narratief' in de Cryptocast De Instagrampagina van Veronique Over de podcast Cryptocurrency are here to stay. In deze wekelijkse podcast gidst Daniël Mol je door het belangrijkste cryptonieuws, langs hypes en trends, voor- en tegenstanders en winst en verlies. In het A-deel bespreken we het laatste nieuws en in het B-deel gaan we in gesprek met een gast. Van cypherpunkpioneers tot grootbanken die aan de haal gaan met stablecoins, van Bitcoin tot Ethereum tot CBDC's. Alles passeert de revue. Reageren? Stuur dan een mail naar cryptocast@bnr.nl Gasten Bart Mol is oprichter en host van Satoshi Radio, en Het Crypto Journaal. Daarnaast is Bart analist bij kennisplatform Bitcoin Alpha. Veronique Estié is econoom, belegger, schrijver en oprichter van YoungTrader. Met haar platform wil ze financiële kennis toegankelijk maken. Host Daniel Mol is redacteur en presentator van de Cryptocast. Hij is sinds 2017 met Bitcoin bezig en kwam in 2021 bij het team van de Cryptocast. Redactie Daniel Mol Matthijs Damsteeg See omnystudio.com/listener for privacy information.

In dieser Episode nehme ich Dich mit zum FIT - Forum für Innovation und Transformation. Eine Konferenz der Kreissparkasse Miesbach Tegernsee. Hier findest Du weitere Infos: [FIT](https://www.fitforum.org/) In meiner Keynote "Wie Wandel gelingt!" spreche ich darüber, warum Transformation nur gelingt, wenn du und deine Mitarbeitenden wirklich emotional an die Zukunft eures Unternehmens glauben. Ich zeige dir, weshalb Wandel weit über Prozessoptimierung hinausgeht und wie du als Führungskraft Orientierung geben kannst – selbst dann, wenn der Weg unklar ist. Außerdem erfährst du, weshalb radikale Kundennutzen-Fokussierung Agilität freisetzt und wie Plattformen wie das FIT Forum regionale Innovationskraft stärken. Kernthemen: - Warum emotionale Bindung der Schlüssel zu echter Transformation ist - Wie du durch radikale Kundennutzen-Fokussierung Klarheit und Agilität erzeugst - Warum Ungewissheit normal ist – und wie du sie für dich nutzen kannst - Welche Rolle du als „Bergführer“ im Wandel einnimmst - Wie das FIT Forum als Innovationsplattform Menschen verbindet und Veränderung beschleunigt Wenn Dir diese Folge gefallen hat, dann freue ich mich über Deine Bewertung mit 5 Sternen bei Apple Podcasts und wenn Du meinen Podcast weiterempfiehlst. Mail mir gerne Deine Gedanken zur Folge unter jw@juergenweimann.com. Lass uns verbinden: [LinkedIN](https://www.linkedin.com/in/juergenweimann/) Liebe Grüße, Jürgen [Abonnier hier meinen Newsletter](https://juergenweimann.com/juergen-weimann-newsletter/)

The debate over immigration reform and ag labor has some big holes on both sides of the argument.

BACK in 2004. I took our kids back to Africa in 2004. Here's what happened. Due to a minor plane crash and having to make the trip overland, our kids went on into the Congo and I stayed behind with no plans for the week in the Central African Republic. THEN the invitations poured in! I happily taught many groups, pastors, deaconesses, school teachers, night watchmen and even high government officials! They were trilled at the positive news of Eden!NOW in 2026! We have two special events coming up! YOU are invited to our Event at the HQ of the American Bible Society on March 21 2026! We'll be presenting the Tru316 Medallion Award to ABS President Dr. Jennifer Holloran and our Keynote speaker will be Dr. Beverly Nyberg! Dr. Nyberg studied at the University of Nebraska and Trinity Evangelical Divinity School. she has been Adjunct Professor at The George Washington University and Senior Consultant at Common Root Consulting. At the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) State Dept. she for 11 years she was responsible for the US Government global programs for children affect by HIV/AIDS. PEPFAR. She also had served with the Peace Corps in Africa and provided field leadership in DR Congo with The Evangelical Free Church Mission. The Tru316 Foundation (www.Tru316.com) is the home of The Eden Podcast with Bruce C. E. Fleming where we “true” the verse of Genesis 3:16. The Tru316 Message is that “God didn't curse Eve (or Adam) or limit woman in any way.” Once Genesis 3:16 is made clear the other passages on women and men become clear too. You are encouraged to access the episodes of Seasons 1-11 of The Eden Podcast for teaching on the seven key passages on women and men. Are you a reader? We invite you to get from Amazon the four books by Bruce C. E. Fleming in The Eden Book Series (Tru316.com/trubooks). Would you like to support the work of the Tru316 Foundation? You can become a Tru Partner here: www.Tru316.com/partner

Ep 278 Pages, Keynote, and Numbers 15 Go Freemium Kuzu database company joins Apple's list of recent acquisitions iOS 26.3 Features: Everything New in iOS 26.3 Tauri 2.0 — The cross-platform app building toolkit Rork — Create mobile app in minutes, using AI OpenClaw, OpenAI and the future | Peter Steinberger jordy: I wasted 80 hours and $800 setting up OpenClaw - so you don't have to. I used Xcode 26.3 to build an iOS app with my voice in just two days - and it was exhilarating Steve Troughton-Smith: In case you missed it, I've been testing the limits of Xcode 26.3's agentic programming support this week, using Codex. This entire app used 7% of my weekly Codex usage limit. Compare that to a single (awful) slideshow in Keynote using 47% of my monthly Apple Creator Studio usage limit. Aditya: Cons of being a software engineer no one really talks about… HackerTyper: Use This Site To Prank Your Friends With Your Coding Skills :) Virtualization Explained: We Install 1TB of RAM for HyperVisors, Virtual Machines, and Docker! Mr. Macintosh: The very first email from space was sent on a Macintosh Portable by James Adamson & Shannon Lucid aboard the Shuttle Atlantis STS-43 Public Domain Remastered — Looney Tunes MEGA Compilation, 118 FULL Episodes in 4K 60FPS Zahvalnice Snimano 20.2.2026. Uvodna muzika by Vladimir Tošić, stari sajt je ovde. Logotip by Aleksandra Ilić. Artwork epizode by Saša Montiljo, njegov kutak na Devianartu

Guest Co-host: Steve Tupper. F-35 Glitch... Swift Fuel UL 100R... Headbutt... A320 Type. All this and more on Uncontrolled Airspace Podcast. Recorded Sep 25, 2025. () [#772] {37:30} [UCAP1113B]

What if growth in 2026 isn't about doing more — but choosing better? In this keynote from Benjamin Mena's Elite Recruiter Sales & BD Summit, Kortney Harmon reframes what winning looks like in today's staffing market.In this episode, you'll hear insights from Kortney Harmon's keynote at Ben Mena's Sales and BD Summit, where she explores why narrowing focus, redesigning revenue strategy, and protecting the right relationships are critical in today's staffing market. As sales cycles lengthen and effort becomes more expensive, Kortney breaks down how intentional account selection, system alignment, and leadership judgment can eliminate wasted activity and margin erosion. From confronting burnout and revenue concentration to building repeatable processes that reduce reliance on heroics, she shares practical frameworks to help firms move from reactive selling to relationship-driven growthWhether you're an agency leader, full-desk producer, or building the next phase of your firm's growth, this episode challenges you to rethink where your effort is going — and whether it's truly compounding.____________Follow Benjamin Mena LinkedIn: LinkedIn: BenjaminBenjamin Mena with Select Source Solutions: hereThe Elite Recruiter Podcast Instagram: https://www.instagram.com/theeliterecruiter/Follow Crelate on LinkedIn: CrelateWant to learn more about Crelate? Book a demo hereSubscribe to our newsletter: The Full Desk Experience

Was haben eine Kinderklinik, ein Tattoo am Hals und eine Stuntfrau gemeinsam? Eine Frau namens Jasmin Dreuw – und eine Geschichte, die dich nicht nur fesseln, sondern tief in deinem Herzen treffen wird. In dieser mitreißenden Keynote – entstanden im Killer Keynote Bootcamp mit Tobias Beck – nimmt dich Jasmin mit auf ihre persönliche Achterbahnfahrt des Lebens. Von einem kleinen Mädchen mit einem seltenen Genfehler, das mehr Zeit im Krankenhaus als auf dem Spielplatz verbrachte, hin zu einer Frau, die ihren Körper aus Flugzeugen stürzt und in brennende Autos klettert – als erfolgreiche Stuntfrau.

Today, on Notable Leaders' Radio, I speak with  Melissa Muir, acclaimed jewelry artist and teacher. She highlights how embracing life's unexpected pivot points opens new paths for creativity, personal growth, and transformation. In today's episode, we discuss: Honor your pivot points. Notice the moments whernt feels like a dead end. What would be different if you chose to see it as a time to redesign? Use every closed door or "mistake" as information for your next step. Allow creativity to be learned. Release the belief that you're "not creative" and give yourself permission to practice, experiment, and grow your skills one imperfect attempt at a time. Come home to your own truth. Gently question inherited beliefs, rules, and expectations so you can build a true relationship with yourself, the divine, and others that feels loving, spacious, and genuinely your. Choose communities that help you flourish. Intentionally seek out people who are curious, creative, and kind, knowing that "creativity breeds creativity" and you don't have to do it alone. Talk gently to your younger self. Revisit the bullied, lonely, or hurting version of you and let them know what's coming, so you can release old pain and stand more fully in who you are now. RESOURCES: Guest Bio: Melissa Muir is a metalsmith, educator, and trusted voice in the jewelry industry, known for bridging traditional craftsmanship with modern tools and techniques. With decades of hands-on experience at the bench, she specializes in jewelry fabrication, welding, stone setting, and emerging technologies such as pulse arc welding and engraving. As an educator and public speaker, Melissa is passionate about making complex processes approachable for both professional jewelers and dedicated hobbyists. Through workshops, online courses, product testing, and in-depth tool reviews, she empowers makers to work more confidently, efficiently, and creatively. Her clear, honest teaching style has made her a go-to resource for jewelers seeking practical knowledge they can immediately apply. Melissa is also the founder of Melissa Muir Metalsmith, where she shares education, demonstrations, and industry insights through video content, webinars, and live events. Her work focuses on raising the standard of jewelry education worldwide while inspiring makers to embrace innovation without losing sight of craftsmanship. Whether at the bench, on stage, or behind the camera, Melissa Muir is dedicated to helping jewelers refine their skills, invest wisely in tools, and rediscover joy in the making process. Website/Social Links: Melissa@melissamuir.com Www.instagram.com/metalsmithmelissa   Www.youtube.com/melissamuir Www.tictok.com/metalsmithmelissa Belinda's Bio:  Belinda is a sought-after Leadership Advisor, Coach, Consultant and Keynote speaker and a leading authority in guiding global executives, professionals and small business owners to become today's highly respected leaders. As the Founder of BelindaPruyne.com, Belinda works with such organizations as IBM, Booz Allen Hamilton, BBDO, The BAM Connection, Hilton, Leidos, Yale School of Medicine, Landis, and the Discovery Channel. Most recently, she redesigned two global internal advertising agencies for Cella, a leader in creative staffing and consulting. She is a founding C-suite and executive management coach for Chief, the fastest-growing executive women's network. Since 2020, Belinda has delivered more than 72 interviews with top-level executives and business leaders who share their inner journey to success; letting you know the truth of what it took to achieve their success in her Notable Leaders Radio podcast. She gained a wealth of expertise in the client services industry as Executive Vice President, Global Director of Creative Management at Grey Advertising, managing 500 people around the globe. With over 20+ years of leadership development experience, she brings industry-wide recognition to the executives and companies she works with. Whether a startup, turnaround, acquisition, or global corporation, executives and companies continue to turn to Pruyne for strategic and impactful solutions in a rapidly shifting economy and marketplace.   Website: Belindapruyne.com Email Address: hello@belindapruyne.com LinkedIn: https://www.linkedin.com/in/belindapruyne  Facebook: https://www.facebook.com/NotableLeadersNetwork.BelindaPruyne/  Twitter: https://twitter.com/belindapruyne?lang=en  Instagram: https://www.instagram.com/belindapruyne/ 

Every year the Chamber sponsors a poll of San Franciscans regarding the health and vitality of our economy and well being of the City by the Bay. The results were unveiled last week at the City Beat breakfast. Mayor Lurie gave the Keynote address and CEO Rodney Fong presided. In today's podcast, Rodney discusses the poll results.

In our February episode, we marked American Heart Month with Dr. Michael Ghalchi, the founder and medical director of Manhattan Cardiovascular Associates and a Clinical Instructor in the Department of Medicine at NYU Grossman School of Medicine. Dr. Ghalchi explained the importance of regular screenings and shared lifestyle habits that can keep your heart strong. In this month's Key Note, Dr. Ghalchi reviews the key health numbers to aim for to help you stay on track and live your best life.  The Takeaway We want to hear from you! Please complete our survey: 1199SEIUBenefits.org/member-feedback. Drop us a line at our social media channels: Facebook // Instagram // YouTube. Find out where you stand heart-wise by making an appointment with your primary care physician. Don't have one? Find one at our Provider Directory: www.1199SEIUBenefits.org/find-a-provider.  Visit the Healthy Living Resource Center for wellness tips, information and resources; www.1199SEIUBenefits.org/healthyliving. Get to know your numbers at www.1199SEIUBenefits.org/healthyhearts. Need support managing chronic conditions such as type 2 diabetes, hypertension or overweight? Learn about our partnerships: visit www.1199SEIUBenefits.org/the-choice-is-yours/ Browse healthy recipes and meal-prep tips at www.1199SEIUBenefits.org/food-as-medicine. Get inspired by fellow members through our Members' Voices series: www.1199SEIUBenefits.org/healthyliving/membervoices. Stop by our Benefits Channel to join webinars on building healthy meals, managing stress and more: www.1199SEIUBenefits.org/videos. Visit our  YouTube channel to view a wide collection of healthy living videos: www.youtube.com/@1199SEIUBenefitFunds/playlists. Sample our wellness classes to exercise body and mind: www.1199SEIUBenefits.org/wellnessevents. Guest Bio Michael Ghalchi, MD, FACC is a board-certified cardiologist and the founder and medical director of Manhattan Cardiovascular Associates, a New York City–based cardiology practice dedicated to making high-quality cardiovascular diagnostics and care accessible, efficient and patient-centered. He is also a Clinical Instructor in the Department of Medicine at NYU Grossman School of Medicine. He graduated summa cum laude from the University of Pennsylvania and earned his medical degree from the New York University School of Medicine.   At Manhattan Cardiovascular Associates, Dr. Ghalchi focuses on delivering timely, evidence-based cardiovascular care supported by advanced in-office diagnostics, streamlined access and a concierge-level patient experience. His clinical work emphasizes early detection, accurate diagnosis and thoughtful management of cardiovascular disease across a broad patient population. Dr. Ghalchi is also the founder and Medical Director of Apollo 360 Health, a digital preventive-care platform designed to extend high-quality cardiovascular and lifestyle medicine beyond the clinic walls. Apollo 360 Health integrates remote monitoring, data-driven insights and multidisciplinary coaching to help patients proactively manage risk factors, improve outcomes and sustain long-term health. Across both organizations, Dr. Ghalchi's mission is to modernize cardiovascular care by combining rigorous clinical standards with innovative delivery models — ensuring patients receive the right care, at the right time, in the setting that best supports lasting health.

Listen and subscribe to Money Making Conversations on iHeartRadio, Apple Podcasts, Spotify, www.moneymakingconversations.com/subscribe/ or wherever you listen to podcasts. New Money Making Conversations episodes drop daily. I want to alert you, so you don’t miss out on expert analysis and insider perspectives from my guests who provide tips that can help you uplift the community, improve your financial planning, motivation, or advice on how to be a successful entrepreneur. Keep winning! Two-time Emmy and Three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald interviewed Shelby Williams.

Listen and subscribe to Money Making Conversations on iHeartRadio, Apple Podcasts, Spotify, www.moneymakingconversations.com/subscribe/ or wherever you listen to podcasts. New Money Making Conversations episodes drop daily. I want to alert you, so you don’t miss out on expert analysis and insider perspectives from my guests who provide tips that can help you uplift the community, improve your financial planning, motivation, or advice on how to be a successful entrepreneur. Keep winning! Two-time Emmy and Three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald interviewed Shelby Williams.

Listen and subscribe to Money Making Conversations on iHeartRadio, Apple Podcasts, Spotify, www.moneymakingconversations.com/subscribe/ or wherever you listen to podcasts. New Money Making Conversations episodes drop daily. I want to alert you, so you don’t miss out on expert analysis and insider perspectives from my guests who provide tips that can help you uplift the community, improve your financial planning, motivation, or advice on how to be a successful entrepreneur. Keep winning! Two-time Emmy and Three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald interviewed Shelby Williams.

I dig into the Kentucky Auditor's report that found over $133 million in questionable spending by the Beshear administration. The report found issues with:

“I hope you continue to be extremely intentional in choosing to be exactly where your feet are every moment that you are.”Lynn WongEpisode Summary:In this keynote episode from Zweig Group's ElevateAEC2025 Conference, Lynn Wong delivers a powerful talk on what it takes to thrive—both personally and collectively—in the architecture, engineering, and construction world. Drawing from her global leadership experience and some transformative moments along the way, Lynn explores where well-being, conscious leadership, and innovation meet.She opens up about her own story: climbing the ladder across three continents, hitting burnout hard, then finding her way back through slowing down and living with intention. Lynn connects the dots between wellness science and team dynamics, the importance of unlearning old patterns, and how to navigate the disruptions reshaping the AEC industry. Her message is clear: make conscious choices, take care of yourself, and build resilience—in your own life and across the profession.Key Takeaways:Intentional Leadership: Being fully present, knowing oneself deeply, and making conscious choices are foundational to thriving as a leader—especially amid rapid industry change.Slowing Down to Speed Up: Sustainable progress in AEC comes not from relentless pace but from mindful “slowing down”—pausing for clarity, reflection, and purposeful action.Personal Well-Being Fuels Teams: Core habits like breathing deeply, moving joyfully, mindful eating, and sleeping gratefully are essential for personal health, which in turn impacts collective performance and creativity.Embrace Unlearning for Innovation: Growth and transformation in organizations and individuals require an openness to “unlearning” old habits and perspectives and a willingness to navigate discomfort.Celebrate Team Strengths: Success in the AEC industry is rooted in collaboration, recognizing individual and team strengths, and honoring human potential in every project.All this and more on this episode of the Zweig Letter podcast.Links referenced in this episode:Connect with Lynn Wong on LinkedInLearn about the Zweig Letter and subscribe: https://thezweigletter.com/Connect with Randy Wilburn on LinkedInGet your FREE Subscription to the Zweig Letter Newsletter.Stay tuned for more

Bright pink suits, big bills, giant golf clubs, and facebook ads targeted at people who like moustaches? Yep, that's exactly what Rich is going to talk about on the Throwback Thursday episode. It's from a keynote he gave recently at the Service Nation Alliance on the topic of guerrilla marketing. What Rich is talking about is using your brains and your ingenuity to generate interest and leads instead of just your checkbook. This is one of the most fun and interesting keynotes Rich gives--and has loads of great ideas that you might want to implement, regardless of how big your company is.

Today, on Notable Leaders' Radio, I speak with you as I launch the new "Still Becoming" series. I highlight how the journey of growth and self-discovery continues long after success is achieved, inviting you to explore the moments of untapped courage, unexpected opportunities, and personal evolution that unfold beyond traditional milestones. In today's episode, we discuss: Explore life beyond achievement. Reflect on the moment when hitting goals and earning recognition stopped answering everything, and consider whether it's time to redesign what success looks like for you now. Listen for your quiet evolution. Notice the subtle inner shifts, new perspectives, expanded freedom, unexpected gentleness with yourself, that change how you see your work, your impact, and what's truly possible. Let the unexpected become a doorway. Revisit the chapters you never planned, a random elevator conversation, a surprise opportunity, a path you "stumbled into", that you now wouldn't give back for anything. Tap your untapped courage. Acknowledge the deeper reservoir of bravery it takes to step away from predictability, trust your inner knowing, and say yes when your path is no longer obvious or linear. Choose meaning over momentum. Ask where you're sprinting on autopilot and where you're ready to consciously trade speed for impact, alignment, and the kind of contribution that actually matters to you. Define what "more" means for you now. Let go of one-size-fits-all ambitions and get curious about your current version of "more" in this season—more joy, more presence, more service, more creativity—and honor that as valid and enough. RESOURCES: Belinda's Bio: Belinda is a sought-after Leadership Advisor, Coach, Consultant and Keynote speaker and a leading authority in guiding global executives, professionals and small business owners to become today's highly respected leaders. As the Founder of BelindaPruyne.com, Belinda works with such organizations as IBM, Booz Allen Hamilton, BBDO, The BAM Connection, Hilton, Leidos, Yale School of Medicine, Landis, and the Discovery Channel. Most recently, she redesigned two global internal advertising agencies for Cella, a leader in creative staffing and consulting. She is a founding C-suite and executive management coach for Chief, the fastest-growing executive women's network. Since 2020, Belinda has delivered more than 72 interviews with top-level executives and business leaders who share their inner journey to success; letting you know the truth of what it took to achieve their success in her Notable Leaders Radio podcast. She gained a wealth of expertise in the client services industry as Executive Vice President, Global Director of Creative Management at Grey Advertising, managing 500 people around the globe. With over 20+ years of leadership development experience, she brings industry-wide recognition to the executives and companies she works with. Whether a startup, turnaround, acquisition, or global corporation, executives and companies continue to turn to Pruyne for strategic and impactful solutions in a rapidly shifting economy and marketplace. Website: Belindapruyne.com Email Address: hello@belindapruyne.com LinkedIn: https://www.linkedin.com/in/belindapruyne  Facebook: https://www.facebook.com/NotableLeadersNetwork.BelindaPruyne/  Twitter: https://twitter.com/belindapruyne?lang=en  Instagram: https://www.instagram.com/belindapruyne/ 

I am happy to welcome you to the inaugural podcast keynote! This is the official episode 400, so if you're listening to this in February there are 399 episodes to scroll beneath this one. I wanted to mark the 400th episode with something--- in episode 200 we had a town hall and it went really well. I am not sure where this will go on Laura's CV, but I am really happy she accepted the invitation to make something new and to be creative with me on this podcast! Dr. Laura Alfrey –is an associate professor at Monash University in Australia her research interests are in HPE and the ways which policy, professional learning and practice contribute to inclusive and educative experiences for everyone. Today she will share her innovative research in fitness testing…. But beyond publishing copious articles, getting cited hundreds of times a year for her work- Laura also serves the field by being on the Editorial Board for Curriculum Studies in HPE, Sport Education and Society, and the Journal of Teaching in Physical Education…AND MANY MORE!This podcast keynote is about fitness testing in PE, from an Australian lens, with a few notes about the American context, and some commentary by US based researchers as well. Here is a link to the video Laura showed: https://www.youtube.com/watch?v=VcH_IErqIXMThis is the article Chuck noted in his comment: Charles B. “Chuck” Corbin (2026)National Youth Fitness Tests and Awards: Dispelling Misconceptions andMisinformation, Journal of Physical Education, Recreation & Dance, 97:1,3-5, DOI: 10.1080/07303084.2025.2579444 To link to this article:https://doi.org/10.1080/07303084.2025.2579444

View this video at https://macmost.com/how-to-keep-using-pages-numbers-and-keynote-if-you-dont-want-apple-creator-studio.html. If you only use Pages, Numbers and Keynote and don't want the Apple Creator Studio subscription, you should get the new apps, and just ignore the subscription features. Here's how to hide some of them away.